Lexaria Bioscience Corp.

86 articles about Lexaria Bioscience Corp.

• Lexaria Announces 2022 Annual Meeting Results

  6/1/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting.

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

  5/26/2022

  Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

  5/25/2022

  Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

• Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

  4/21/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.

• Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

  4/14/2022

  Lexaria Bioscience Corp. announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.

• Lexaria Provides Update on Human Nicotine Study NIC-H22-1

  4/12/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.

• Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

  2/2/2022

  Lexaria Bioscience Corp. announces positive findings in an animal study evaluating DehydraTECH TM processing of the phosphodiesterase inhibitor.

• Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

  1/18/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants".

• Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

  12/29/2021

  Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.

• Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

  12/14/2021

  Lexaria Bioscience Corp. announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.

• Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

  12/8/2021

  Lexaria Bioscience Corp. is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECH TM -processed cannabidiol reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise.

• Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4

  11/3/2021

  Lexaria Bioscience Corp. announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease.

• Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol

  11/1/2021

  Lexaria Bioscience Corp. has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity

• Lexaria's Technology Proven to Deliver Oral THC More Effectively

  10/13/2021

  Lexaria Bioscience Corp. is pleased to announce that its recent oral tetrahydrocannabinol absorption study THC-A21-1 revealed that DehydraTECH TM -THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

• Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

  10/5/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

• Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Lexaria Bioscience Corp. announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

• Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

  9/8/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced it is formally beginning the process towards an Investigational New Drug application filing with the Food and Drug Administration with its DehydraTECH-processed cannabidiol as a prospective registered pharmaceutical treatment for hypertension.

• Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period

  9/7/2021

  Lexaria Bioscience Corp. is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH TM -processed cannabidiol for potential application against hypertension.

• Lexaria Receives US$3,817,643 From Warrant Exercises

  7/26/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purchase warrants.

• Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

  7/22/2021

  Lexaria Bioscience Corp. is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.